Lübke, Johannes http://orcid.org/0000-0003-0767-1504
Naumann, Nicole
Metzgeroth, Georgia
Kreil, Sebastian
Brand, Timo
Horny, Hans-Peter
Sotlar, Karl
Cross, Nicholas C. P.
Fabarius, Alice
Valent, Peter
Hofmann, Wolf-Karsten
Reiter, Andreas
Schwaab, Juliana
Funding for this research was provided by:
José Carreras Leukämie-Stiftung (DJCLS 08R/2020)
Austrian Science Fund (SFB F4704-B20)
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
Received: 7 November 2022
Accepted: 13 March 2023
First Online: 4 April 2023
Declarations
:
: The study design adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board of the Medical Faculty of Mannheim, Heidelberg University, Germany.
: Written informed consent was provided by all patients.
: Disclosures of conflict of interest: H.-P.H. served as a consultant for Novartis and Blueprint. P.V. received a research grant from Blueprint and Celgene, served as a consultant in a midostaurin trial with Novartis, and received consultancy honoraria from Blueprint, Deciphera, Novartis, Celgene and Pfizer. A.R. was a member of the Study Steering Committee (SSC) for the global trial of midostaurin in advanced systemic mastocytosis (AdvSM) (Novartis), the Response Adjudication Committee (RAC) for studies of avapritinib in AdvSM (Blueprint Medicines), and the SSC for the phase II trial of ripretinib in AdvSM (Deciphera Pharmaceuticals); has received funding for the conduct of these trials; and has received honoraria and reimbursement of travel expenses from Novartis, Blueprint Medicines and Deciphera Pharmaceuticals. J.S. has served as a member in the advisory board of Blueprint for studies of avapritinib in indolent SM and received honoraria from Novartis.